AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.290

+0.000

Volume:92.67K

Turnover:26.75K

Market Cap:72.42M

PE:-3.16

High:0.290

Open:0.285

Low:0.280

Close:0.290

Loading ...

Overview Company News Filings

Recce Pharmaceuticals Ltd - R327g Safe and Well Tolerated With No Serious Adverse Events

THOMSON REUTERS

Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial of Recce® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

THOMSON REUTERS

Recce Pharmaceuticals releases positive data from Phase II trial of topical gel for skin infections

Recce Pharmaceuticals' Phase 2 Trial Shows Topical Gel Safe, Well-Tolerated

MT Newswires Live

BRIEF-Recce Pharmaceuticals Seeks Trading Halt

Recce Pharmaceuticals Ltd - Seeks Trading Halt Pending Announcement on Phase Ii Clinical Trial Data

THOMSON REUTERS

Recce Pharmaceuticals Doses All Patients in Phase Ii Trial of Recce® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Receives Approval for Phase Iii Trial of R327g for Dfis in Indonesia

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Preliminary Data Shows Complete Cure or Significant Improvement With R327g

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Full Data Analysis Expected in Q1 2025

THOMSON REUTERS

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Recce Pharmaceuticals Completes Dosing Patients for Phase Two Wound Infection Trial

MT Newswires Live

Recce Pharmaceuticals Receives Approval From Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of Recce® 327 Topical Gel in Diabetic Foot Infections

THOMSON REUTERS

Recce Pharmaceuticals Secures Approval for Diabetic Food Infection Clinical Trial in Indonesia; Shares Rise 5%

MT Newswires Live

Recce Pharmaceuticals advances global reach with Indonesia’s approval for Phase 3 Diabetic Foot Infection Trial

The Market Herald

Recce Pharmaceuticals Ltd-Regulatory Approval for Registrational Phase 3 R327g Trial

THOMSON REUTERS

BRIEF-Recce Pharmaceuticals Seeks Trading Halt

Recce Pharmaceuticals Ltd - Trading Halt Pending Announcement on Phase 3 Diabetic Foot Ulcer Infection Approval

THOMSON REUTERS

Recce Pharmaceuticals Ltd-Trading Halt

THOMSON REUTERS

Recce Pharmaceuticals Granted Australia Patent for Recce® Anti-Infectives

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RCE.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.29,"timestamp":1745475120000,"preClose":0.29,"halted":0,"volume":92674,"delay":0,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":167272518,"shares":249728760,"eps":-0.091765,"marketStatus":"Market Closed","change":0,"latestTime":"04-24 16:12:00 AEST","open":0.285,"high":0.29,"low":0.28,"amount":26745,"amplitude":0.034483,"askPrice":0.29,"askSize":63653,"bidPrice":0.28,"bidSize":131092,"shortable":3,"etf":0,"ttmEps":-0.091765,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745798400000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1745452800000,1745474400000]],"volumeRatio":0.5204539043732951,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":167272518,"roa":"-217.58%","roe":"-1277.62%","lyrEps":-0.099727,"volumeRatio":0.5204539043732951,"shares":249728760,"dividePrice":0,"high":0.29,"amplitude":0.034483,"preClose":0.29,"low":0.28,"week52Low":0.275,"pbRate":"-14.52","psRate":"7.55","week52High":0.688,"institutionHeld":0,"latestPrice":0.29,"committee":0.346294,"eps":-0.091765,"divideRate":0,"volume":92674,"delay":0,"ttmEps":-0.091765,"open":0.285,"prevYearClose":0.48,"prevWeekClose":0.29,"prevMonthClose":0.357,"prevQuarterClose":0.357,"fiveDayClose":0.29,"twentyDayClose":0.362,"sixtyDayClose":0.461},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512101210","title":"Recce Pharmaceuticals Ltd - R327g Safe and Well Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2512101210","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512101210?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2512010149","title":"Recce Pharmaceuticals Reports Positive Data From Phase Ii Trial of Recce® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway","url":"https://stock-news.laohu8.com/highlight/detail?id=2512010149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512010149?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:00","pubTimestamp":1739970002,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA1WRNVK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2512992976","title":"Recce Pharmaceuticals releases positive data from Phase II trial of topical gel for skin infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2512992976","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512992976?lang=en_us&edition=fundamental","pubTime":"2025-02-17 11:35","pubTimestamp":1739763313,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  has released positive patient data analysis from a Phase II clinical trial of its Recce 327 topical gel  for the treatment of acute bacterial skin and skin structure infections.The company designed the open-label trial to assess the efficacy and safety of R327G in 30 male and female patients, with one patient withdrawing due to pre-existing pain at a wound site deemed unrelated to R327G.After seven days of treatment, 25 out of the remaining 29 patients (86%) treated with R327G had a successful clinical response, while 27 patients (93%) had achieved the primary efficacy endpoint by the 14-day mark.The trial met all primary and secondary endpoints relating to the safety and tolerability, efficacy and plasma pharmacokinetics of R327G when applied directly to an infected area.Recce chief medical advisor Dr Alan Dunton said the trial results underscored the potential of R327G to meet critical unmet medical needs in infection treatment.“These results reflect the broad-","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Recce-Pharmaceutical-ASX-RCE-327-topical-gel-Phase-2-clinical-trial-results.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/02/Recce-Pharmaceutical-ASX-RCE-327-topical-gel-Phase-2-clinical-trial-results.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/recce-pharmaceuticals-positive-data-trial-topical-gel-skin-infections/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2512600989","title":"Recce Pharmaceuticals' Phase 2 Trial Shows Topical Gel Safe, Well-Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2512600989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512600989?lang=en_us&edition=fundamental","pubTime":"2025-02-17 10:46","pubTimestamp":1739760362,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said phase two clinical trials of its topical gel Recce 327  for the treatment of acute bacterial skin and skin structure infections  showed that the gel is safe and well-tolerated with no serious adverse effects on patients, according to a Monday filing with the Australian bourse.After 14 days of treatment, 27 out of 29 patients treated with R327G achieved the primary efficacy endpoint, the filing said.The study's assessments observed wound healing, with the potential for full recovery after 14 days, the filing added.Based on the trial's results, experts believe the company's registrational phase 3 study for diabetic foot infections can achieve a statistically \"significant\" positive endpoint after enrolling around 100 patients, the filing added.Shares of the company rose past 2% in recent Monday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2511155357","title":"BRIEF-Recce Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2511155357","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511155357?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:58","pubTimestamp":1739408301,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Seeks Trading HaltFeb 13 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:RECCE PHARMACEUTICALS LTD - SEEKS TRADING HALT PENDING ANNOUNCEMENT ON PHASE II CLINICAL TRIAL DATAFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2511553541","title":"Recce Pharmaceuticals Ltd -  Seeks Trading Halt Pending Announcement on Phase Ii Clinical Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2511553541","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511553541?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:57","pubTimestamp":1739408264,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505874466","title":"Recce Pharmaceuticals Doses All Patients in Phase Ii Trial of Recce® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2505874466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505874466?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2505744215","title":"Recce Pharmaceuticals Ltd - Receives Approval for Phase Iii Trial of R327g for Dfis in Indonesia","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744215","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744215?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505744212","title":"Recce Pharmaceuticals Ltd - Preliminary Data Shows Complete Cure or Significant Improvement With R327g","url":"https://stock-news.laohu8.com/highlight/detail?id=2505744212","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505744212?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505442457","title":"Recce Pharmaceuticals Ltd - Full Data Analysis Expected in Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2505442457","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505442457?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA9GXJ34:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2505742891","title":"Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2505742891","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505742891?lang=en_us&edition=fundamental","pubTime":"2025-01-22 21:00","pubTimestamp":1737550800,"startTime":"0","endTime":"0","summary":"Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327G. “R327G has made significant progress over the last year, confirming its safety profile and demonstrating impressive efficacy as a topical gel formulation, especially considering the high degree of bacterial resistance present in many of the patients being treated in this Phase II trial,” said James Graham, CEO of Recce Pharmaceuticals. “We look forward to the full dataset, which we expect will further support R327G's progress toward regulatory evaluation.”Thus far, no serious adverse events have been reported, and all patients dosed with R327G have achieved positive outcomes. The full set of data will be reviewed by the Data Safety Monitoring Board with complete results expected to be announced in Q1 2025. Recce is expected to initiate a Phase III study of R327G in Australia in H1 2025 that will serve as a registrational trial for the U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recce-pharmaceuticals-doses-patients-phase-130000740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4135","BK4570","TGA","LU0498741114.HKD","BK4585","LU0368265764.SGD","LU1223083913.SGD","LU1223082519.USD","GAIN","BK4213","XJO.AU","BK4006","BK4533","LU0498741890.SGD","LU0496367417.USD","XKO.AU","AU","BK7001","LU1223082196.USD","LU0724618789.USD","BK7096","XAO.AU","TGA.AU","LU0055631609.USD","USA","BK4017","LU0788108826.HKD","RCE.AU","AMR","BK4588","BK4522"],"gpt_icon":0},{"id":"2505296513","title":"Recce Pharmaceuticals Completes Dosing Patients for Phase Two Wound Infection Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2505296513","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505296513?lang=en_us&edition=fundamental","pubTime":"2025-01-21 12:04","pubTimestamp":1737432274,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  completed the dosing of 30 patients for a phase two trial investigating the use of the Recce 327 topical gel in patients with acute bacterial skin and skin structure infections, according to a Tuesday filing with the Australian bourse.The open-label study aims to assess the safety and tolerability, plasma pharmacokinetics, and efficacy of the topical gel following daily application for seven to 14 days, the filing said.Results from the study are anticipated within the first quarter, per the filing.Shares of the pharmaceutical firm rose past 2% in recent Tuesday trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2490090143","title":"Recce Pharmaceuticals Receives Approval From Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of Recce® 327 Topical Gel in Diabetic Foot Infections","url":"https://stock-news.laohu8.com/highlight/detail?id=2490090143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490090143?lang=en_us&edition=fundamental","pubTime":"2024-12-10 21:00","pubTimestamp":1733835605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241210:nTUAC9MWSF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2490979796","title":"Recce Pharmaceuticals Secures Approval for Diabetic Food Infection Clinical Trial in Indonesia; Shares Rise 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490979796","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490979796?lang=en_us&edition=fundamental","pubTime":"2024-12-09 11:17","pubTimestamp":1733714268,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals (ASX:RCE) received approval from Indonesia's Drug and Food Authority to start a registrational phase 3 clinical trial of its Recce 327 topical gel in diabetic foot infections, ac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0426417589.USD","XJO.AU","LU0994945656.USD","LU1043141123.HKD","LU2238339852.HKD","XKO.AU","RCE.AU","BK4125","AUD","LU0426412945.USD","XAO.AU","BK7096","LU0345774631.USD"],"gpt_icon":0},{"id":"2490765527","title":"Recce Pharmaceuticals advances global reach with Indonesia’s approval for Phase 3 Diabetic Foot Infection Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490765527","media":"The Market Herald","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490765527?lang=en_us&edition=fundamental","pubTime":"2024-12-09 07:18","pubTimestamp":1733699880,"startTime":"0","endTime":"0","summary":"Sydney-based Recce Pharmaceutical Ltd  has reached a landmark stage in its bid to commercialise a topical gel that would treat diabetic foot infections , gaining approval for a Phase 3 trial in Indonesia to assess the gel in question, RECCE 327 .Two achievements have made this possible: The first being Recce’s gaining of approval from the Indonesian Drug and Food Regulatory Authority – Badan POM – for the Registrational Phase 3 clinical trial.Alongside this, Recce’s human ethics committee has approved commencement of patient dosing, and the alignment of both means the trial is on-track to begin this quarter.In fact, the upward trend of diabetes in the country has been acknowledged as a serious health issue since the 1980s, and today it has one of the world’s largest patient populations for the condition.In fact, it is one of the largest DFI studies in the world, and the first of its kind within Indonesia.“The approval of Recce Pharmaceuticals’ Phase 3 clinical trial is an important ste","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/recce-pharmaceuticals-advances-global-reach-with-indonesias-approval-for-phase-3-diabetic-foot-infection-trial-2024-12-09/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2490509597","title":"Recce Pharmaceuticals Ltd-Regulatory Approval for Registrational Phase 3 R327g Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490509597","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490509597?lang=en_us&edition=fundamental","pubTime":"2024-12-09 06:05","pubTimestamp":1733695509,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241208:nTUE3X40XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2489016125","title":"BRIEF-Recce Pharmaceuticals Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489016125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489016125?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:23","pubTimestamp":1733351003,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Seeks Trading HaltDec 5 (Reuters) - Recce Pharmaceuticals Ltd RCE.AX:TRADING HALTTRADING HALT PENDING ANNOUNCEMENT ON PHASE 3 DIABETIC FOOT ULCER INFECTION APPROVALFurther company coverage: RCE.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUEHQ9KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"gpt_icon":0},{"id":"2489125707","title":"Recce Pharmaceuticals Ltd - Trading Halt Pending Announcement on Phase 3 Diabetic Foot Ulcer Infection Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2489125707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489125707?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:21","pubTimestamp":1733350916,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUEHQ9KG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2489125083","title":"Recce Pharmaceuticals Ltd-Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2489125083","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2489125083?lang=en_us&edition=fundamental","pubTime":"2024-12-05 06:21","pubTimestamp":1733350916,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241204:nTUEHQ9KG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"gpt_icon":0},{"id":"2486801829","title":"Recce Pharmaceuticals Granted Australia Patent for Recce® Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2486801829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486801829?lang=en_us&edition=fundamental","pubTime":"2024-11-27 21:00","pubTimestamp":1732712438,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241127:nFWN3MY1B9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":62,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[]}}